Pfizer clinches the top spot in the competitive 2025 Super Bowl ad race, promising groundbreaking visibility during the big ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

A trio of high-octane income stocks -- sporting an average yield of 6.65% -- can fatten investors' pocketbooks in 2025 (and ...

Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.

The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.

Alloy Therapeutics Inc., a biotechnology ecosystem company, has joined forces with Pfizer Inc., to develop a new platform ...